Videos de Experimentos Relacionados
Terapia combinada de dosis bajas con rosiglitazona y metformina para prevenir la diabetes mellitus tipo 2 (ensayo
Bernard Zinman1, Stewart B Harris, Jan Neuman
1Department of Medicine, Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada. zinman@lunenfeld.ca
Lancet (London, England)
|July 8, 2010
Resumen
Las dosis bajas de rosiglitazona y metformina redujeron significativamente el desarrollo de la diabetes tipo 2 en pacientes con intolerancia a la glucosa. Esta terapia combinada demostró ser eficaz para la prevención de la diabetes con efectos secundarios manejables.
Área de la Ciencia:
- Endocrinología Endocrinología.
- Enfermedades Metabólicas Las enfermedades metabólicas.
- Los ensayos clínicos son ensayos clínicos.
Sus antecedentes:
- La epidemia de diabetes tipo 2 requiere estrategias efectivas de prevención.
- El ensayo CANOE evaluó la terapia combinada de dosis bajas para la prevención de la diabetes.
Objetivo del estudio:
- Para investigar la eficacia de la terapia de combinación de dosis bajas de rosiglitazona y metformina en la prevención de la diabetes tipo 2.
- Evaluar la seguridad y eficacia de este enfoque terapéutico en pacientes con tolerancia a la glucosa.
Principales métodos:
- Ensayo controlado aleatorizado doble ciego con 207 pacientes con tolerancia a la glucosa reducida.
- Los participantes recibieron rosiglitazona (2 mg) y metformina (500 mg) dos veces al día o placebo durante una mediana de 3,9 años.
- Resultado primario: el tiempo hasta el desarrollo de la diabetes a través de la prueba de tolerancia oral a la glucosa o la glucosa plasmática en ayunas.
Principales resultados:
- Significativamente menos participantes en el grupo de tratamiento activo desarrollaron diabetes (14%) en comparación con el placebo (39%).
- Reducción del riesgo relativo del 66% y reducción del riesgo absoluto del 26% para la incidencia de diabetes.
- El 80% del grupo de tratamiento regresó a la tolerancia normal a la glucosa frente al 53% en el grupo de placebo. Se observó un aumento de la diarrea en el grupo de tratamiento.
Conclusiones:
- La terapia combinada de dosis bajas de rosiglitazona y metformina es altamente efectiva en la prevención de la diabetes tipo 2 en personas con tolerancia a la glucosa disminuida.
- La terapia combinada demostró un perfil de seguridad favorable con respecto a los eventos adversos importantes.
- Este enfoque ofrece una estrategia viable para la prevención de la diabetes.
Videos de Conceptos Relacionados
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...